Drugs / rTSST-1v
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02340338 | Jul 2014 → Jun 2015 | infectious disease with sepsis, toxic shock syndrome | Biomedizinische Forschungs gmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02814708 | May 2016 → May 2020 | toxic shock syndrome | Biomedizinische Forschungs gmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rTSST-1v | “We aimed to assess the safety, tolerability, and immunogenicity of a recombinant detoxified toxic shock syndrome toxin-1 variant (rTSST-1v) vaccine in adult volunteers.” PMID 27296693 ↗ Jun 2016 |
| Modality | Vaccine | “We aimed to assess the safety, tolerability, and immunogenicity of a recombinant detoxified toxic shock syndrome toxin-1 variant (rTSST-1v) vaccine in adult volunteers.” PMID 27296693 ↗ Jun 2016 |